News from AAN 2026: BTKi
At the end of April, the annual meeting of the American Academy of Neurology (AAN) took place in Chicago. I had the opportunity to attend the congress on site and therefore want to summarize some
Continue reading
Tag: BTKi
News about Fenebrutinib
BTKi are considered to be the beacon of hope in the MS community, as they are supposed to specifically target and slow down the creeping parts of MS. BTKi are very small molecules that go
Continue reading
New Year, new on BTKi: PERSEUS Study misses the primary endpoint
First of all, I would like to wish all readers of MS-DocBlog a happy and successful new year. – Stay healthy and hopeful, despite all adversities. Speaking of adversities – this brings us right back
Continue reading
BTKi – the direction is right.
On November 10, 2025, Roche released a press release announcing that Fenebrutinib has reached its primary endpoint in the first Phase III trial (FENhance 2) of two similarly designed pivotal Phase III trials (FENhance 1
Continue reading
Development of MS Therapies
There has been a lot of progress in the development of MS therapy, since the first interferon for multiple sclerosis came on the market in the mid-90s. There are now almost 20 immunomodulatory agents approved.
Continue readingNew Findings on BTKi – the Tolebrutinib Study Program
At this year’s ECTRIMS Meeting in Copenhagen, the data from the study program of the Bruton-Tyrosine-Kinase (BTK) inhibitor Tolebrutinib was presented. And what can I say – fortunately there were positive news this time.
Continue reading
Merry Christmas and a Happy New Year
The year 2023 is slowly coming to an end. Therefore, as usual at this point, I would like to wish my readers a blessed Christmas season, as well as luck and health for the coming
Continue reading
ECTRIMS 2023 in Milan – “We are halfway home, but we are not all the way there”
This year’s annual meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place from October 12 to 14 in Milan. This most important scientific MS congress discusses the most important
Continue reading
MS-Docblog – Details on the New Class of Active Substances of BTKi
Bruton tyrosine kinase inhibitors, or BTKi for short, are by no means new. They are known from cancer therapy and have been adapted for the treatment of neurologically degenerative diseases. So, will there soon be
Continue reading
ECTRIMS 2021 (3): New Therapeutic Concepts
One of the most exciting topics of large international congresses is the outlook for new therapies that may be able to bring added value in the future. As an immunological treatment strategy, we will probably
Continue reading
